# Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies

> **NCT00048737** · PHASE1,PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 70 (actual)

## Conditions studied

- Lymphoma
- Leukemia

## Interventions

- **DRUG:** Zevalin Radioimmunotherapy
- **DRUG:** Rituximab
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide
- **PROCEDURE:** Allogeneic Stem Cell Transplantation

## Key facts

- **NCT ID:** NCT00048737
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-10
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2013-06-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00048737

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00048737, "Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00048737. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*